{"id":"act-128800","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Edema"},{"rate":"5-15%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting the binding of endothelin-1 to its receptors, ACT-128800 reduces vasoconstriction and lowers blood pressure, which can be beneficial in treating pulmonary arterial hypertension.","oneSentence":"ACT-128800 is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:18:51.582Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT07362017","phase":"PHASE3","title":"Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2026-01","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":300},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT03232073","phase":"PHASE3","title":"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-07-05","conditions":"Multiple Sclerosis","enrollment":877},{"nctId":"NCT05552196","phase":"PHASE1","title":"A Study of Ponesimod in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT03882255","phase":"PHASE1","title":"A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2019-03-20","conditions":"Healthy","enrollment":52},{"nctId":"NCT02425644","phase":"PHASE3","title":"Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2015-06-04","conditions":"Multiple Sclerosis","enrollment":1133},{"nctId":"NCT01006265","phase":"PHASE2","title":"Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-10-01","conditions":"Multiple Sclerosis","enrollment":464},{"nctId":"NCT01093326","phase":"PHASE2","title":"Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-05-12","conditions":"Multiple Sclerosis","enrollment":353},{"nctId":"NCT01208090","phase":"PHASE2","title":"ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-10-31","conditions":"Psoriasis","enrollment":326},{"nctId":"NCT02461134","phase":"PHASE2","title":"Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD","status":"TERMINATED","sponsor":"Actelion","startDate":"2016-09-29","conditions":"Chronic Graft Versus Host Disease","enrollment":1},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT02907177","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)","status":"TERMINATED","sponsor":"Actelion","startDate":"2017-03-30","conditions":"Multiple Sclerosis","enrollment":136},{"nctId":"NCT02068235","phase":"PHASE1","title":"Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2014-08","conditions":"Healthy","enrollment":17},{"nctId":"NCT02223832","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-02","conditions":"Healthy","enrollment":20},{"nctId":"NCT02136888","phase":"PHASE1","title":"Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-08","conditions":"Healthy","enrollment":116},{"nctId":"NCT02126956","phase":"PHASE1","title":"Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2009-03","conditions":"Pharmacokinetics","enrollment":6},{"nctId":"NCT02029482","phase":"PHASE1","title":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2010-04","conditions":"Safety and Tolerability","enrollment":16},{"nctId":"NCT00852670","phase":"PHASE2","title":"ACT-128800 in Psoriasis","status":"COMPLETED","sponsor":"Actelion","startDate":"2008-10","conditions":"Plaque Psoriasis","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACT-128800","genericName":"ACT-128800","companyName":"Actelion","companyId":"actelion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACT-128800 is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor. Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}